Propranolol HCl

• CAT Number: A000769
• CAS Number: 318-98-9
• Molecular Formula: C16H21NO2.HCl
• Molecular Weight: 295.8
• Purity: ≥95%
• Target: Adrenergic Receptor
• Solubility: >12.4mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;hydrochloride
• InChI: InChI=1S/C16H21NO2.ClH/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16;/h3-9,12,14,17-18H,10-11H2,1-2H3;1H
• InChIKey: ZMRUPTIKESYGQW-UHFFFAOYSA-N
• SMILES: CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl

Propranolol HCl (CAS 318-98-9) is a competitive non-selective beta-adrenergic receptors inhibitor with antianginal, antiarrhythmic, and antihypertensive properties (IC50 of 12 nM). Propranolol competitively antagonizes beta-adrenergic receptors, thereby inhibiting beta-adrenergic reactions, such as vasodilation, and negative chronotropic and inotropic effects.

Reference

1. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338. doi: 10.1016/bs.podrm.2017.02.006. Epub 2017 Apr 6.Propranolol.Al-Majed AA(1), Bakheit AHH(2), Abdel Aziz HA(3), Alajmi FM(1), AlRabiah H(1).

 

Propranolol is a noncardioselective β-blocker. It is reported to have membrane-stabilizing properties, but it does not own intrinsic sympathomimetic activity. Propranolol hydrochloride is used to control hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy. It is also used to control symptoms of sympathetic overactivity in the management of hyperthyroidism, anxiety disorders, and tremor. Other indications cover the prophylaxis of migraine and of upper gastrointestinal bleeding in patients with portal hypertension. This study provides a detailed, comprehensive profile of propranolol, including formulas, elemental analysis, and the appearance of the drug. In addition, the synthesis of the drug is described. The chapter covers the physicochemical properties, including X-ray powder diffraction, pK, solubility, melting point, and procedures of analysis (spectroscopic, electrochemical, and chromatographic). In-depth pharmacology is also presented (pharmacological actions, therapeutic dosing, uses, Interactions, and adverse effects and precautions). More than 60 references are given as a proof of the abovementioned studies.

 

2. World J Emerg Surg. 2017 Mar 2;12:11. doi: 10.1186/s13017-017-0124-7. eCollection 2017.

Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis.Manzano-Nunez R(1)(2), García-Perdomo HA(2), Ferrada P(3), Ordoñez Delgado 

CA(4), Gomez DA(2), Foianini JE(5).

 

BACKGROUND: The objective of this systematic review was to determine the effectiveness and safety of propranolol compared to placebo or usual care for improving clinical relevant outcomes in severely burned patients (TBSA >20%).

METHODS: Relevant articles from randomized controlled trials were identified by a literature search in MEDLINE, EMBASE, and CENTRAL. We included trials involving patients with a severe burn (>20% of total body surface area affected). Trials were eligible if they evaluated propranolol and compared to usual care or placebo. Two investigators independently assessed articles for inclusion and exclusion criteria and selected studies for the final analysis. We conducted a meta-analysis using a random-effects model.

RESULTS: We included ten studies in our systematic review. These studies randomized a total of 1236 participants. There were no significant differences between propranolol and placebo with respect to mortality (RD -0.02 [95% CI -0.06 to 0.02]), sepsis (RD -0.03 [95% CI -0.09 to 0.04]), and the overall hospital stay (MD -0.37 [-4.52 to 3.78]). Propranolol-treated adults had a decrease in requirements of blood transfusions (MD -185.64 [95% CI -331.06 to -40.43]) and a decreased heart rate (MD -26.85 [95% CI -39.95 to -13.75]).

CONCLUSIONS: Our analysis indicates that there were no differences in mortality or sepsis in severely burned patients treated with propranolol compared with those who had usual care or placebo. However, the use of propranolol in these patients resulted in lower requirements of blood transfusion and lower values of heart rate. The evidence synthesized in this systematic review is limited to conclude that propranolol reduces the length of hospital stay among severely burned patients. Future trials should assess the impact of propranolol on clinically relevant outcomes such as mortality and adverse events.

 

3. Br Med J. 1966 Nov 26;2(5525):1311-2.Propranolol.